HomeAI · summaries
Storia in 2 fonti
The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs — TFN
The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup Graph is now moving from platform science to drug creation.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
tech.eu
Graph Therapeutics brings total funding to over $10M to advance precision immunology
Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics…
- ·
techfundingnews.com
The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs — TFN
The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup Graph is now moving from platform science to drug…